Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
5/31/2026, 12:00:00 AM
On May 31, 2026, presented positive preliminary Phase 1/2 data for linvoseltamab at the ASCO annual meeting; estimated >5% price impact due to positive clinical results for a key pipeline drug, expected.
Korean Translation
2026년 5월 31일, ASCO 연례회의에서 린보셀타맙의 임상 1/2상 긍정적 데이터 발표함. 임상 결과에 따른 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM